Te­va hit by an­oth­er PhI­II set­back on CGRP pain drug fre­manezum­ab, but there’s no pulling back now as ri­vals race ahead

Te­va has al­ready been pushed back to a fol­low-up shot at the CGRP mi­graine drug mar­ket. Now it’s al­so lost a Phase III round that could put the com­pa­ny even fur­ther be­hind the mar­ket lead­ers.

The em­bat­tled com­pa­ny $TE­VA re­port­ed this morn­ing that their late-stage pro­gram for fre­manezum­ab failed in pa­tients with chron­ic clus­ter headaches. They’re aban­don­ing that in­di­ca­tion, but plan to push ahead with their study in episod­ic clus­ter headaches.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER